Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy

Christian G. Figueroa-Espada; Michael J. Mitchell; Rachel S. Riley; Samuel Hofbauer

doi:10.1016/j.addr.2020.09.006

Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy

Christian G. Figueroa-Espada, Michael J. Mitchell, Rachel S. Riley, Samuel Hofbauer

Biomedical Engineering

Rowan University

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

A major challenge to treating diseases during pregnancy is that small molecule therapeutics are transported through the placenta and incur toxicities to the developing fetus. The placenta is responsible for providing nutrients, removing waste, and protecting the fetus from toxic substances. Thus, the placenta acts as a biological barrier between the mother and fetus that can be exploited for drug delivery. Nanoparticle technologies provide the opportunity for safe drug delivery during pregnancy by controlling how therapeutics interact with the placenta. In this Review, we present nanoparticle drug delivery technologies specifically designed to exploit the placenta as a biological barrier to treat maternal, placental, or fetal diseases exclusively, while minimizing off-target toxicities. Further, we discuss opportunities, challenges, and future directions for implementing drug delivery technologies during pregnancy.

Original language	American English
Pages (from-to)	244-261
Number of pages	18
Journal	Advanced Drug Delivery Reviews
Volume	160
DOIs	https://doi.org/10.1016/j.addr.2020.09.006
State	Published - May 2020

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1016/j.addr.2020.09.006

Cite this

@article{5501cfb464ba40138a61b8cf7b220c04,

title = "Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy",

abstract = "A major challenge to treating diseases during pregnancy is that small molecule therapeutics are transported through the placenta and incur toxicities to the developing fetus. The placenta is responsible for providing nutrients, removing waste, and protecting the fetus from toxic substances. Thus, the placenta acts as a biological barrier between the mother and fetus that can be exploited for drug delivery. Nanoparticle technologies provide the opportunity for safe drug delivery during pregnancy by controlling how therapeutics interact with the placenta. In this Review, we present nanoparticle drug delivery technologies specifically designed to exploit the placenta as a biological barrier to treat maternal, placental, or fetal diseases exclusively, while minimizing off-target toxicities. Further, we discuss opportunities, challenges, and future directions for implementing drug delivery technologies during pregnancy.",

author = "Figueroa-Espada, {Christian G.} and Mitchell, {Michael J.} and Riley, {Rachel S.} and Samuel Hofbauer",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",

year = "2020",

month = may,

doi = "10.1016/j.addr.2020.09.006",

language = "American English",

volume = "160",

pages = "244--261",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy

AU - Figueroa-Espada, Christian G.

AU - Mitchell, Michael J.

AU - Riley, Rachel S.

AU - Hofbauer, Samuel

PY - 2020/5

Y1 - 2020/5

N2 - A major challenge to treating diseases during pregnancy is that small molecule therapeutics are transported through the placenta and incur toxicities to the developing fetus. The placenta is responsible for providing nutrients, removing waste, and protecting the fetus from toxic substances. Thus, the placenta acts as a biological barrier between the mother and fetus that can be exploited for drug delivery. Nanoparticle technologies provide the opportunity for safe drug delivery during pregnancy by controlling how therapeutics interact with the placenta. In this Review, we present nanoparticle drug delivery technologies specifically designed to exploit the placenta as a biological barrier to treat maternal, placental, or fetal diseases exclusively, while minimizing off-target toxicities. Further, we discuss opportunities, challenges, and future directions for implementing drug delivery technologies during pregnancy.

AB - A major challenge to treating diseases during pregnancy is that small molecule therapeutics are transported through the placenta and incur toxicities to the developing fetus. The placenta is responsible for providing nutrients, removing waste, and protecting the fetus from toxic substances. Thus, the placenta acts as a biological barrier between the mother and fetus that can be exploited for drug delivery. Nanoparticle technologies provide the opportunity for safe drug delivery during pregnancy by controlling how therapeutics interact with the placenta. In this Review, we present nanoparticle drug delivery technologies specifically designed to exploit the placenta as a biological barrier to treat maternal, placental, or fetal diseases exclusively, while minimizing off-target toxicities. Further, we discuss opportunities, challenges, and future directions for implementing drug delivery technologies during pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=85096224114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096224114&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2020.09.006

DO - 10.1016/j.addr.2020.09.006

M3 - Review article

C2 - 32956719

SN - 0169-409X

VL - 160

SP - 244

EP - 261

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

ER -

Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this